drugset / Trial / NCT07165132
Study of RYZ401 in Subjects With Solid Tumors Expressing SSTRs.
NaSequentialOpen-labelTreatment
Summary
The primary objectives are to determine the recommended Phase 2 dose (RP2D) and optimal treatment regimen, characterize safety and tolerability, and evaluate preliminary efficacy of RYZ401 in subjects with NETs and other selected solid tumors expressing SSTRs.
Timeline
- Start
- 2025-12-03
- Primary completion
- 2027-02
- Completion
- 2033-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | RYZ401 | Other / unclassified | — | — |